文献速递基础与转化研究组学、生物样本库与精准医学

司美格鲁肽对代谢功能障碍相关脂肪性肝炎代谢、炎症和纤维化通路的调节

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.
PubMed 文献 · Nat Med · 2025-07-21

该研究在两种临床前MASH模型中显示司美格鲁肽改善纤维化和炎症的组织学标志物,并降低肝脏纤维化和炎症相关基因通路表达。对临床试验中MASH患者血清的适体蛋白质组分析识别出72种与MASH缓解及司美格鲁肽治疗显著相关的蛋白质,独立真实世界队列验证了该特征。数据提示司美格鲁肽可能使MASH相关的循环蛋白质组逆转为健康个体的模式。

要点

  • 在两种临床前MASH模型中,司美格鲁肽改善纤维化和炎症的组织学标志物。
  • 司美格鲁肽降低肝脏纤维化相关和炎症相关基因通路的表达。
  • 临床试验MASH患者血清中72种蛋白质与MASH缓解及司美格鲁肽治疗显著相关。

核心结论

  • 数据提示司美格鲁肽可能使MASH相关的循环蛋白质组逆转为健康个体中观察到的蛋白质组模式。

研究设计与样本

  • 研究包括两种临床前MASH模型、一项临床试验中MASH患者血清的适体蛋白质组分析,以及一个独立真实世界队列。
  • 临床试验中识别出72种与MASH缓解和司美格鲁肽治疗显著相关的蛋白质。

主要发现

  • 在两种临床前MASH模型中,司美格鲁肽改善纤维化和炎症的组织学标志物,并降低肝脏纤维化相关和炎症相关基因通路的表达。
  • 临床试验MASH患者血清中72种蛋白质与MASH缓解及司美格鲁肽治疗显著相关,其中大多数与代谢相关,数种涉及纤维化和炎症。
  • 独立真实世界队列显示,同样的72种蛋白质在MASH患者相对于健康个体中差异表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. Here we show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways. Aptamer-based proteomic analyses of serum samples from patients with MASH in a clinical trial identified 72 proteins significantly associated with MASH resolution and semaglutide treatment, with most related to metabolism and several implicated in fibrosis and inflammation. An independent real-world cohort verified the pathophysiological relevance of this signature, showing that the same 72 proteins are differentially expressed in patients with MASH relative to healthy individuals. Taken together, these data suggest that semaglutide may revert the circulating proteome associated with MASH to the proteomic pattern observed in healthy individuals.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Jara M, Norlin J, Kjær MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025. PMID: 40691365. doi:10.1038/s41591-025-03799-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。